<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01983644</url>
  </required_header>
  <id_info>
    <org_study_id>REDIRECT</org_study_id>
    <nct_id>NCT01983644</nct_id>
  </id_info>
  <brief_title>RECO Flow Restoration Device Versus Solitaire FR With the Intention for Thrombectomy Study</brief_title>
  <acronym>REDIRECT</acronym>
  <official_title>RECO Flow Restoration Device Versus Solitaire FR With the Intention for Thrombectomy Study: a Prospective Randomised Control Trial(REDIRECT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jinling Hospital, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jinling Hospital, China</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Endovascular therapy is increasingly used for patients with moderate-to-severe acute ischemic
      stroke.This study will compare the efficacy and safety of RECO(a novel, self-expanding stent
      retriever) with Solitaire FR within 8 hours of stroke onset caused by the large vessel
      occlusion.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      RECO is a novel, self-expanding stent retriever, designed to yield rapid flow restoration in
      acute cerebral ischaemia. The proposed study is a multicenter, randomized, prospective,
      parallel-group, open-label clinical trial with a blinded outcome, to test the RECO(a novel,
      self-expanding stent retriever), as compared with Solitaire FR stent retriever.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Revascularization Status</measure>
    <time_frame>Post-procedure, immediate=at the end of the procedure, per last angiogram during treatment</time_frame>
    <description>Revascularization, defined as at least TICI 2a in the vascular territory treated at end of the neuro interventional procedure Thrombolysis in Cerebral Infarction (TICI) grading system for perfusion (ie blood flow through a vessel) Grade 0:No Perfusion. No antegrade flow beyond the point of occlusion. Grade 1:Penetration With Minimal Perfusion. Grade 2:Partial Perfusion. Grade 2a:Only partial filling (&lt;2/3) of the entire vascular territory is visualized. Grade 2b:Complete filling of all of the expected vascular territory is visualized, but slower . Grade 3:Complete Perfusion.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Outcomes at 90 Days</measure>
    <time_frame>90-day</time_frame>
    <description>Good clinical outcome is defined as an modified Rankin Scale (mRS) score of 0-2 at 90 days. mRS 0-2 indicates functional independence 0 - No symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>intracranial hemorrhages</measure>
    <time_frame>24 hours</time_frame>
    <description>Incidence of intracranial hemorrhages(ICH) within 24(-6/+12)hours post procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>all-cause mortality at 90 days</measure>
    <time_frame>procedure through 90 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>RECO thrombectomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IA thrombectomy is executed by RECO flow restoration device which is a novel, self-expanding stent retriever designed to yield rapid flow restoration in acute cerebral ischaemia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Solitaire FR thrombectomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IA thrombectomy is executed by Solitaire FR flow restoration device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>RECO flow restoration device</intervention_name>
    <description>RECO flow restoration device is a novel, self-expanding stent retriever designed to yield rapid flow restoration in acute cerebral ischaemia.</description>
    <arm_group_label>RECO thrombectomy</arm_group_label>
    <other_name>RECO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Solitaire FR flow restoration device</intervention_name>
    <description>Solitaire FR flow restoration device has been approved by the FDA and CFDA.</description>
    <arm_group_label>Solitaire FR thrombectomy</arm_group_label>
    <other_name>Solitaire FR</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. age (18-80 years)

          2. acute ischemic stroke

          3. within 8 hours after symptom onset

          4. a large-vessel confirmed by CTA/MRA (eg, internal carotid, middle cerebral M1 and/or
             M2 segments)

          5. NIHSS(≥8 and ≤24)

          6. patients or their legally authorised representatives provided signed, informed
             consent.

        Exclusion Criteria:

          1. CT or MRI evidence of intracranial haemorrhage/tumor

          2. major ischaemic infarction (acute ischaemic change in more than a third of the middle
             cerebral artery territory)

          3. NIHSS(≥25 and ≤7)

          4. severe sustained hypertension (systolic blood pressure &gt;185 mm Hg or diastolic blood
             pressure &gt;110 mm Hg)

          5. baseline glucose concentrations of less than 2·7 mmol/L or higher than 21.6 mmol/L

          6. known haemorrhagic diathesis, coagulation factor deficiency, or oral anticoagulant
             therapy with an international normalised ratio of more than 1.7

          7. treatment with heparin within 48 h with a partial thromboplastin time more than two
             times the laboratory normal, baseline platelet count of less than 100×10^9/L

          8. history of severe allergy (worse than rash) to contrast medium or nitinol

          9. pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xinfeng Liu, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Neurology, Jinling Hospital, Nanjing 210002, China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xinfeng Liu, MD</last_name>
    <phone>86-25-84801861</phone>
    <email>xfliu2@vip.163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Daping Hospital</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meng Zhang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fuzhou General Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hang Lin</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital of Xiamen University</name>
      <address>
        <city>Xiamen</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weihong Zheng</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhongnan Hospital of Wuhan University</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yumin Liu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>First People's Hospital of Changzhou</name>
      <address>
        <city>Changzhou</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ya Peng</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Jinling Hospital, Nanjing University School of Medicine</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210002</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xinfeng Liu, MD</last_name>
      <phone>86-25-84801861</phone>
      <email>xfliu2@vip.163.com</email>
    </contact>
    <contact_backup>
      <last_name>Yunfei Han, MD</last_name>
      <phone>86-25-80860454</phone>
      <email>hanshiyu1982@163.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Nantong University</name>
      <address>
        <city>Nantong</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kaifu Ke</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Second Affiliated Hospital of Soochow University</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yongjun Cao</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yangzhou First People's Hospital</name>
      <address>
        <city>Yangzhou</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei Wang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Qingdao University</name>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yong Zhang</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 4, 2013</study_first_submitted>
  <study_first_submitted_qc>November 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 14, 2013</study_first_posted>
  <last_update_submitted>December 13, 2016</last_update_submitted>
  <last_update_submitted_qc>December 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Jinling Hospital, China</investigator_affiliation>
    <investigator_full_name>Xinfeng Liu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>acute ischemic stroke,endovascular recanalization</keyword>
  <keyword>mechanical thrombectomy</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

